Obermatt
See Similar Stocks →

Gain Therapeutics

NMQ:GANX · US36269B1052
BiotechnologyX-Small

360° View

59
Price/Sales—
Price/Earnings29
Price/Book84
Dividend Yield1
Revenue Growth1
Profit Growth94
Capital Growth23
TSR 52w18
Leverage52
Liquidity86
Refinancing47
Combined69
Analyst Opinions63
Pro Holdings13
Opinion Changes50
Market Pulse83

Profile

CountryUSA
IndustryBiotechnology
SizeX-Small
TypePublic Company
ExchangeNASDAQGM
Founded2020
Employees25
Websitegaintherapeutics.com
ISINUS36269B1052
Last UpdateApr 2, 2026
Index & Theme
Machine LearningChronic DiseasesNeurologyCentral Nervous SystemNeuroscienceGenetic DisorderOncology

Description

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. The company develops novel small molecule therapeutics to treat diseases across several therapeutic area…

Analysis

Gain Therapeutics's 360° View rank of 59 places it above its peer average — better than 59% of its true peers.

It's growing slowly (34) and on the expensive side (45). On safety it is very well financed (88), and the market shows favorable sentiment (53). Taken together, its Combined rank of 69 reads as above its peer average.

360° rank · history

1007550250
59
2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
—
—
—
—
Price/Earnings
29
—
—
—
Price/Book
84
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
45
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Gain Therapeutics with its peers
Connect Biopharma Holdings
NMQ:CNTB
55
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Voyager Therapeutics
NSQ:VYGR
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Assembly Biosciences
NSQ:ASMB
33
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Corvus Pharmaceuticals
NMQ:CRVS
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nkarta
NSQ:NKTX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →